Cargando…
Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study
Recent whole-genome sequencing efforts led to the identification of IDH1(R132) mutations in AML patients. We studied the prevalence and clinical implications of IDH1 genomic alterations in pediatric and adult AML. Diagnostic DNA from 531 AML patients treated on Children’s Oncology Group trial COG-AA...
Autores principales: | Ho, Phoenix A., Alonzo, Todd A., Kopecky, Kenneth J., Miller, Kristen L., Kuhn, Julia, Zeng, Rong, Gerbing, Robert B., Raimondi, Susana C., Hirsch, Betsy A., Oehler, Vivian, Hurwitz, Craig A., Franklin, Janet L., Gamis, Alan S., Petersdorf, Stephen H., Anderson, Jeanne E., Reaman, Gregory H., Baker, Laurence H., Willman, Cheryl L., Bernstein, Irwin D., Radich, Jerald P., Appelbaum, Frederick R., Stirewalt, Derek L., Meshinchi, Soheil |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945692/ https://www.ncbi.nlm.nih.gov/pubmed/20376086 http://dx.doi.org/10.1038/leu.2010.56 |
Ejemplares similares
-
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531
por: Voigt, Andrew P., et al.
Publicado: (2017) -
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
por: Aplenc, Richard, et al.
Publicado: (2020) -
Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group
por: Nagarajan, Rajaram, et al.
Publicado: (2019) -
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2015) -
Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2016)